Nuclear Medicine Europe (ex AIPES) represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of the art imaging permits non invasive visualisation of organs ,function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few and as such is an integral part of patient care.
Nuclear medicine is unique in being able to diagnose early detection of disease and permit early treatment before progression of disease improving the prognosis for the patient. Nuclear Medicine Europe provides a wide scope of services & partnerships on behalf of our members. We maintain close contacts with EU commission, politicians, the European Medicines Agency, academia & the media. We also have partnerships with key EU Patient associations & other professional bodies in the healthcare field.
Working closely with the EANM & associated medical societies, our objective is to raise awareness of the role & benefit of NM & collectively continue to further research into molecular healthcare & its benefits for the citizens of Europe.
Nuclear Medicine Europe (ex AIPES) is a European Industrial Association working on promotion, awareness and defence of Nuclear Medicine and Molecular Healthcare in Europe. We are active in the field of Imaging and Therapy with Molecular and Radioactive Tracers. The main objective of our association in this field is to ensure the promotion of the economic and/or commercial interests of its Members, in particular, by all means allowing to increase the awareness to the benefits of the products and services they offer.
In addition to the main activity described here above, our association may represent the common interest of the Members in relation with the European Institutions, with other national and international authorities and in dealing with other scientific, educational or professional association groups or societies, such as EANM, EFPIA, CERN.
Emanating from the first clinical use of nuclear medicine tracers and therapeutics in the 1950s, a clinical discipline and supporting industry began to emerge during the 1970s in the United States, Europe and Japan. By 1985 this activity was considered appropriate for regulation by the European Union, and a directive bringing radiopharmaceuticals in line with all other drug substances was introduced.
In 1987, all interested radiopharmaceutical companies agreed to form the Association of Radiopharmaceutical Producers Europe (ARPE) which was formalised shortly afterwards as a European economic interest group (EEIG).
ARPE’s initial focus on pharmaceutical regulations was very successful and led to an agreement with the EEC for rational registration process. In addition to these activities ARPE also became a focal point for dealing with threats to the continuing success of radiopharmaceuticals in Europe. For example, a threat to disrupt supply of a key raw material in the production of radiopharmaceutical preparations was addressed by focussed lobbying with governments, regulators and industrial partners.
By the mid 1990s the professional organisation representing nuclear medicine physicians in Europe (EANM) provided an opportunity for ARPE to become directly involved in a strategic collaboration to develop the speciality. In order to appropriately respond to this challenge, ARPE broadened its statutes to encompass hardware and equipment companies and renamed itself the Association of Radiopharmaceutical Producers and Equipment Suppliers (ARPES). ARPES was closely involved with several EANM projects including the funding of a cost benefit study for nuclear cardiology and a contribution to the establishment of a strategic vision for nuclear medicine in Europe. By the end of the 1990s most members had broadened their scope and were now engaged in multi-modality in-vivo diagnostic activities.
To reflect this reality a new name AIPES (Association of Imaging Producers and Imaging Suppliers), with the mission to foster industry collaboration across all fields of in-vivo diagnosis, was adopted in 2001.
During its relatively brief history our industry association has experienced massive technological, commercial and regulatory change. Despite this change, our members remain committed to providing the highest standards of product and service excellence to physicians worldwide and ultimately the patients that they serve.
In May 2019, AIPES change its name and visual identity to become Nuclear Medicine Europe.